
Cipla’s Albuterol Sulfate HFA Inhalation Aerosol is the first AB-rated generic therapeutic equivalent version of Merck Sharp & Dohme Corp’s Proventil® HFA (Albuterol Sulfate) Inhalation Aerosol.1
Proventil® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved.
When you receive Cipla’s Albutrol Sulfate HFA Inhalation Aerosol at the pharmacy, you may notice that the device looks different from your previous inhaler. Cipla’s Albuterol Sulfate HFA inhaler contains the same medication as Proventil® HFA (Albuterol Sulfate 90mcg).

Albuterol
Dosage

Total
Doses

Dose Counting Mechanism

Shelf-life
Proventil® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved.

Dose Indicator display window shows remaining number of puffs of medicine
Each canister contains 200 puffs and the doses required for priming the inhaler.
1
Display window background moves after every 10 puffs.
2
Number inside dose indicator window changes after every 20 puffs.
3
Only 20 puffs left.
Need a refill or a new prescription.
Albuterol sulfate inhalation aerosol is a prescription inhaled medicine used in patients aged 4 years and older to:
It is not known if Albuterol sulfate inhalation aerosol is safe and effective in children younger than 4 years of age.
For the treatment or prevention of sudden asthma symptoms, the usual dosage for adults and children aged 4 years and older is 2 sprays repeated every 4 to 6 hours. In some patients, a dosage of 1 spray every 4 hours may be enough.
For exercise-induced bronchospasm, or EIB, the usual dose for adults and children aged 4 years and older is 2 sprays taken 15 to 30 minutes before exercise.
Cipla’s Albuterol sulfate inhalation aerosol is:
Cipla’s Albuterol sulfate inhalation aerosol does not contain:
Before you use this inhaler for the first time, you need to get it ready. This is called “priming”. This will ensure there is enough medicine in each spray. You do not need to do this every time, but if you did not use your Albuterol sulfate Inhalation Aerosol for more than 2 weeks, you should re-prime it before use.
Please refer to the Instructions for Use Video or the full Prescribing Information for a guide on how to prime your inhaler.
Contact us at 1-866-604-3268 and we would be happy to help you walk through detailed priming instructions over the phone.
The soft click may be confusing as the dose is not yet released. You must continue with the actuation process and continue to press further to ensure the release of the dose.
Albuterol sulfate inhalation aerosol has a built-in dose counter that counts down each time a spray is released. At any given time, the dose counter shows how many sprays of albuterol are left in your inhaler. When the dose counter turns red and reads ‘20’, you should refill your prescription or ask your doctor if you need another prescription. When it turns ‘0’ replace your inhaler.
At any given time, the dose counter shows the number of sprays left in the canister. The dose indicator display window will continue to move after every 10 puffs. The number changes after every 20 puffs. At 20, the color will change to red. The dose counter stops counting when it reaches ‘0’. The dose counter cannot be reset, and it is permanently attached to the metal canister. Do not try to change the numbers or take the counter off the metal canister.
You could have medicine build-up blocking the spray. Cleaning your inhaler with warm water can help fix this.
Please refer to the Instructions for Use Video or the full Prescribing Information for a guide on how to properly clean your inhaler.
Contact us at 1-866-604-3268 and we would be happy to help you walk through detailed cleaning or priming instructions over the phone.
The two openings at bottom are only for assembly purposes and has no impact on the flow of medication or the functionality of the device.
Cipla’s Albuterol sulfate inhalation aerosol can be used with any anti-static spacer as long as a proper fit is achieved with the inhaler and spacer. Consult with your prescriber to ensure device compatibility and proper usage.
Albuterol sulfate inhalation aerosol may cause serious side effects, including:
Call your healthcare provider or get emergency medical care if you get any of the following symptoms of a serious allergic reaction:
Common adverse effects of treatment with inhaled albuterol include palpitations, chest pain, rapid heart rate, tremor, or nervousness.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Cipla at 1-866-604-3268.
Store at 20°C to 25°C (68°F to 77°F). Store the inhaler with the mouthpiece down. Avoid exposing your inhaler to extreme heat and cold. For best results, canister should be at room temperature before use.
Used or expired inhalers should be treated as biomedical waste and must be disposed as per your local guidelines. Consult with your physician or pharmacist for safe disposal instructions.
Please consult with your physician as this is highly dependent on patient’s underlying, co-existing conditions.
Albuterol sulfate inhalation aerosol is indicated in adults and children 4 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.
Contraindications: Albuterol sulfate inhalation aerosol is contraindicated in patients with a history of hypersensitivity to albuterol or any other Albuterol sulfate inhalation aerosol components.
General: Albuterol sulfate, as with all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension; in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus; and in patients who are unusually responsive to sympathomimetic amines. Clinically significant changes in systolic and diastolic blood pressure have been seen in individual patients and could be expected to occur in some patients after use of any beta-adrenergic bronchodilator.
Large doses of intravenous albuterol have been reported to aggravate preexisting diabetes mellitus and ketoacidosis. As with other beta-agonists, albuterol may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects. The decrease is usually transient, not requiring supplementation.
Common adverse effects include: upper respiratory tract infection, stuffy nose, nausea, tremor, vomiting, rapid heart rate, nervousness, fever, inhalation site sensation, allergic reaction.
Pregnancy, Labor/Delivery, Nursing Mothers:
Albuterol sulfate inhalation aerosol should be used during pregnancy and labor only if the benefits clearly outweigh the risk. Caution should be exercised when albuterol sulfate is administered to a nursing woman.
Drug Interactions include beta-blockers, diuretics, albuterol-digoxin, monoamine oxidase inhibitors or tricyclic antidepressants.
You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Cipla at 1-866-604-3268.
Please see the full Prescribing Information for additional Important Safety Information.
Albuterol sulfate inhalation aerosol is indicated in adults and children 4 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.
Contraindications: Albuterol sulfate inhalation aerosol is contraindicated in patients with a history of hypersensitivity to albuterol or any other Albuterol sulfate inhalation aerosol components.
General: Albuterol sulfate, as with all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension; in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus; and in patients who are unusually responsive to sympathomimetic amines. Clinically significant changes in systolic and diastolic blood pressure have been seen in individual patients and could be expected to occur in some patients after use of any beta-adrenergic bronchodilator.
Large doses of intravenous albuterol have been reported to aggravate preexisting diabetes mellitus and ketoacidosis. As with other beta-agonists, albuterol may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects. The decrease is usually transient, not requiring supplementation.
Common adverse effects include: upper respiratory tract infection, stuffy nose, nausea, tremor, vomiting, rapid heart rate, nervousness, fever, inhalation site sensation, allergic reaction.
Pregnancy, Labor/Delivery, Nursing Mothers:
Albuterol sulfate inhalation aerosol should be used during pregnancy and labor only if the benefits clearly outweigh the risk. Caution should be exercised when albuterol sulfate is administered to a nursing woman.
Drug Interactions include beta-blockers, diuretics, albuterol-digoxin, monoamine oxidase inhibitors or tricyclic antidepressants.
You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Cipla at 1-866-604-3268.
Please see the full Prescribing Information for additional Important Safety Information.